DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

Laurent Humeau,Cornelia L Trimble,Matthew P Morrow,Xuefei Shen,Michael Dallas,David B Weiner,Jean D Boyer,Jian Yan,Kimberly A Kraynyak,Albert Sylvester,Mary Giffear, Kathy Marcozzipierce,Divya Shah,Kate E Broderick,Amir S Khan,Jessica Lee,Niranjan Y Sardesai, Mark Bargarazzi

Journal for ImmunoTherapy of Cancer（2014）

引用 1|浏览117

暂无评分

摘要

Meeting abstracts The Phase II study, designated HPV-003 ([NCT01304524][1]), assessed the safety and efficacy of VGX-3100 in 167 women with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or CIN 3 and HPV-16 or -18. The randomized, placebo-controlled, double-blind study, was stratified by

查看译文

关键词

Placebo Group, Cervical Intraepithelial Neoplasia, Cell Mediate Immune Response, Vaccine Dose, Successful Phase

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要